Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445988 | 1.00 | GAA (0.73) | GAAOPRM1OPRK1OPRD1GRIN2D | |
| SCHEMBL22865971 | 1.00 | GAA (0.73) | GAAOPRM1OPRK1OPRD1GRIN2D | |
| SCHEMBL21600566 | 1.00 | GAA (0.73) | GAAOPRM1OPRK1OPRD1GRIN2D | |
| SCHEMBL21600228 | 1.00 | GAA (0.73) | GAAOPRM1OPRK1OPRD1GRIN2D | |
| SCHEMBL14371362 | 0.87 | GAA (0.79) | GAAOPRM1OPRK1OPRD1MRGPRX2 | |
| SCHEMBL16454868 | 0.85 | GAA (0.76) | GAAOPRM1OPRK1OPRD1GRIN2D | |
| SCHEMBL21148321 | 0.85 | GAA (1.00) | GAAOPRM1OPRK1OPRD1MRGPRX2 | |
| SCHEMBL14371364 | 0.85 | GAA (1.00) | GAAOPRM1OPRK1OPRD1MRGPRX2 | |
| SCHEMBL12717587 | 0.85 | GAA (1.00) | GAAOPRM1OPRK1OPRD1MRGPRX2 | |
| SCHEMBL12717590 | 0.85 | GAA (1.00) | GAAOPRM1OPRK1OPRD1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| US-11534436-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-27 | — | — | US | disclosed |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-01-07 | — | — | US | disclosed |
| US-10736890-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-11 | — | — | US | disclosed |
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-06-06 | — | — | US | disclosed |
| US-10287250-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-14 | — | — | US | disclosed |
| US-20180016237-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-01-18 | — | — | US | disclosed |
| US-9682936-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-9656961-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRK1 3/4885 |
| US-10287250-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | GAA 374/4885OPRM1 159/4885OPRK1 646/4885 |
| US-20180016237-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885OPRK1 676/4885 |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRK1 3/4885 |
| US-11534436-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRK1 3/4885 |
| US-10736890-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.